葵花药业集团股份有限公司关于2022年员工持股计划股份出售完毕暨终止的公告

Core Viewpoint - The announcement details the completion and termination of the 2022 employee stock ownership plan of Kew Flower Pharmaceutical Group Co., Ltd, highlighting the sale of all shares held under this plan and the associated performance metrics for unlocking shares [1][5]. Group 1: Employee Stock Ownership Plan Overview - The employee stock ownership plan was implemented in August 2022, with approval from the board and shareholders [1]. - A total of 2,950,060 shares were transferred to the employee stock ownership plan at a price of 7.50 yuan per share, representing 0.51% of the company's total share capital [2]. Group 2: Share Lock-up and Unlocking Conditions - The plan had a duration of 48 months, with shares unlocking in three phases based on performance metrics: 30% after 12 months, 35% after 24 months, and 35% after 36 months [3]. - The first two unlocking phases were successful, allowing for the release of 885,018 shares and 1,032,521 shares, respectively, while the third phase did not meet performance criteria, resulting in no shares being unlocked [3]. Group 3: Subsequent Arrangements Post-Plan - All shares under the employee stock ownership plan were sold through secondary market trading, completing the plan and leading to its early termination [5]. - The company will proceed with asset liquidation and distribution following the completion of the employee stock ownership plan [5].